login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
TREVI THERAPEUTICS INC (TRVI) Stock News
USA
- NASDAQ:TRVI -
US89532M1018
-
Common Stock
11.37
USD
-0.09 (-0.79%)
Last: 11/14/2025, 8:00:01 PM
11.6
USD
+0.23 (+2.02%)
After Hours:
11/14/2025, 8:00:01 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
TRVI Latest News, Press Relases and Analysis
All
Press Releases
a day ago - By: Chartmill
Trevi Therapeutics Inc (NASDAQ:TRVI) Reports Q3 2025 Results, Narrows Loss and Outlines Phase 3 Plans
2 days ago - By: Trevi Therapeutics, Inc.
Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
9 days ago - By: Trevi Therapeutics, Inc.
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025
11 days ago - By: Trevi Therapeutics, Inc.
Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference
a month ago - By: Trevi Therapeutics, Inc.
Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting
a month ago - By: Benzinga
- Mentions:
PRPH
ABP
WORX
COSM
...
12 Health Care Stocks Moving In Friday's After-Market Session
2 months ago - By: Trevi Therapeutics, Inc.
Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025
3 months ago - By: Trevi Therapeutics, Inc.
Trevi Therapeutics to Participate in Upcoming September Conferences
3 months ago - By: Trevi Therapeutics, Inc.
Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
3 months ago - By: Benzinga
- Mentions:
GSAT
PGY
ADV
REAL
...
Earnings Scheduled For August 7, 2025
4 months ago - By: Trevi Therapeutics, Inc.
Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025
4 months ago - By: Trevi Therapeutics, Inc.
Trevi Therapeutics to Participate in Upcoming August Conferences
5 months ago - By: Trevi Therapeutics, Inc.
Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism
5 months ago - By: Trevi Therapeutics, Inc.
Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
5 months ago - By: Trevi Therapeutics, Inc.
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
6 months ago - By: Trevi Therapeutics, Inc.
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
6 months ago - By: Trevi Therapeutics, Inc.
Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
6 months ago - By: Trevi Therapeutics, Inc.
Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
6 months ago - By: Yahoo Finance
- Mentions:
VRT
DDOG
AGNC
AAPL
...
Vertiv Holdings Co (NYSE:VRT) Strong Sales Pipeline Drives Mizuho Target Hike to $125 Despite Tariff Headwinds
6 months ago - By: Yahoo Finance
- Mentions:
BIOA
SPT
VRT
LLY
...
H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating
6 months ago - By: Yahoo Finance
- Mentions:
SPT
CZR
BNS
FNV
...
Needham Maintains Buy Rating on Sprout (SPRT) After Positive Customer Review
6 months ago - By: Yahoo Finance
- Mentions:
BNS
SPT
CZR
FNV
...
BMO Capital Maintains Hold Rating on Scotiabank (BNS) As Provision for Credit Losses Increase
6 months ago - By: Trevi Therapeutics, Inc.
Trevi Therapeutics to Participate in Upcoming June Conferences
6 months ago - By: Trevi Therapeutics, Inc.
Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
6 months ago - By: Zacks Investment Research
Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?
6 months ago - By: Trevi Therapeutics, Inc.
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
7 months ago - By: Trevi Therapeutics, Inc.
Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025
8 months ago - By: Trevi Therapeutics, Inc.
Trevi Therapeutics to Participate in Upcoming April Investor Conferences
8 months ago - By: Avalo Therapeutics
- Mentions:
AVTX
COLL
BHVN
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
8 months ago - By: Trevi Therapeutics, Inc.
Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates
Please enable JavaScript to continue using this application.